Recent News
Read ArticleRheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a definition of remission in gout.
Allopurinol during acute attacks does not worsen attacks or outcomes.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/PcOGD8umRw
Dr. John Cush @RheumNow ( View Tweet)
When Gout Flares, So Does the Cardiovascular System
We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title https://t.co/HCUQVaor4f
Dr. John Cush @RheumNow ( View Tweet)
Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ https://t.co/zN41GC5T15
Dr. John Cush @RheumNow ( View Tweet)
Upgrading & Maximizing the Classics
Panelists: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikuls Dr. Jack Cush (moderator)
https://t.co/gO4CQD2f19 https://t.co/ESSLL0iK8F
Dr. John Cush @RheumNow ( View Tweet)
2 T2T RCTs of 383 gout pts starting allopurinol - 31% had tophi. At 12 mos achieving target uric acid (<0.36mmol/L) was same in pts with and without tophi (70.3 vs 73.6), as was the %gout flares in month 11 (71.4% vs 79.7%; p=0.21). Allopurinol T2T success not influenced by https://t.co/zr7K8Y2Bqz
Dr. John Cush @RheumNow ( View Tweet)
Gout patients have ↑ Cancer risk and ↓ risk of Parkinsons.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/dJrXMFb9OS
Dr. John Cush @RheumNow ( View Tweet)
New Avacopan Analysis Sent to FDA
MedPage Today
After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.
Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for severe anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis on the market.
Read Article
Tips for safe use of allopurinol
These are tips and hopefully the patients are abstaining from moderate alcohol and are not tipsy! Here are 5 tips that may not be totally obvious.
Read Article
$2 Million in Research Grants for Juvenile Arthritis
July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.
Equally important is that 2026 marks a 50 year anniversary for Pediatric Rheumatology in the United States.
Read Article
Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow. Take this week's RheumIQ quiz to test your knowledge!
https://t.co/UNoKMdclnj https://t.co/XpGfx1fJLu
Dr. John Cush @RheumNow ( View Tweet)
Swimming Reduces Disability from Low Back Pain
Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically https://t.co/OfxsvRjyJg
Dr. John Cush @RheumNow ( View Tweet)
"The best medicine I know for rheumatism is to thank the Lord that it ain't the gout."
— Josh Billings (Henry Wheeler Shaw)
Dr. John Cush @RheumNow ( View Tweet)
Evidence-Based Dietary Recommendations for Gout
Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is the most common inflammatory arthritis https://t.co/uIrSeOjxJZ
Dr. John Cush @RheumNow ( View Tweet)
3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z
Dr. John Cush @RheumNow ( View Tweet)
Interferon-α as an Immunologic Driver of Sjögren's Disease
Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/0BDDvR5cUB
Dr. John Cush @RheumNow ( View Tweet)
Genetic Risk Loci in Fibromyalgia
Researchers examined genetic data drawn from 11 different worldwide cohorts, that included from more than 2.5 million adults, of which 55,000 had been diagnosed with fibromyalgia. They identified DNA sequence variants in 26 regions of the genome that affect the risk of developing fibromyalgia. Many of the genes implicated in these regions are involved in brain and nerve function. This is the largest fibromyalgia GWAS to date.
Read Article
Persistence of education and monitoring is crucial to optimal gout management
Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/wDvgwUg2P1
Dr. John Cush @RheumNow ( View Tweet)
Pragmatism in Gout: How therapeutic choices can have multiple benefits
Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ
Dr. John Cush @RheumNow ( View Tweet)
Retrospective study of 2187 RA pts initiating menopausal hormone Tx (MHT) vs 8,205 unexposed controls. VTE incidence higher among MHT users (6.49 vs 3.3/1000PY). MHT use was associated with a 92% signif increased risk of VTE in RA (adj HR: 1.92), mostly DVT risk (aHR: 2.26)
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Gout Lessons from the Clinic Part 3
DERM on RheumNow (July 2026)
New, Advanced Therapies in Gout
Systemic Burden of Gout Part 1
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Videos include: Gout Management in Patients with CKD, Gout and CVD, and Gout & Obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
A JAKi After Primary or Secondary TNFi Nonresponse in RA (SELECT-SWITCH)
Daily Gem
SGLT2 inhibitors lower serum urate AND reduce gout flares — and may close the mortality gap (CV mortality benefit) and offer renal protection.
--